HRP20211880T1 - Sastavi i metode za liječenje i profilaksu infekcija kirurškog mjesta - Google Patents
Sastavi i metode za liječenje i profilaksu infekcija kirurškog mjesta Download PDFInfo
- Publication number
- HRP20211880T1 HRP20211880T1 HRP20211880TT HRP20211880T HRP20211880T1 HR P20211880 T1 HRP20211880 T1 HR P20211880T1 HR P20211880T T HRP20211880T T HR P20211880TT HR P20211880 T HRP20211880 T HR P20211880T HR P20211880 T1 HRP20211880 T1 HR P20211880T1
- Authority
- HR
- Croatia
- Prior art keywords
- substrate
- biodegradable
- use according
- matrix composition
- surgery
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 15
- 238000000034 method Methods 0.000 title claims 8
- 238000011282 treatment Methods 0.000 title claims 4
- 238000011321 prophylaxis Methods 0.000 title claims 3
- 208000031650 Surgical Wound Infection Diseases 0.000 title 1
- 239000000758 substrate Substances 0.000 claims 29
- 239000011159 matrix material Substances 0.000 claims 12
- 238000001356 surgical procedure Methods 0.000 claims 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 10
- 208000015181 infectious disease Diseases 0.000 claims 8
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 229920000229 biodegradable polyester Polymers 0.000 claims 4
- 239000004622 biodegradable polyester Substances 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 3
- 239000001506 calcium phosphate Substances 0.000 claims 3
- 125000005313 fatty acid group Chemical group 0.000 claims 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 239000011707 mineral Substances 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 150000003904 phospholipids Chemical group 0.000 claims 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 210000002249 digestive system Anatomy 0.000 claims 2
- 229960003722 doxycycline Drugs 0.000 claims 2
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 claims 2
- 229960001172 doxycycline hyclate Drugs 0.000 claims 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 239000004633 polyglycolic acid Substances 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 150000003432 sterols Chemical group 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 229910052882 wollastonite Inorganic materials 0.000 claims 2
- 239000010456 wollastonite Substances 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010062255 Soft tissue infection Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 229910052661 anorthite Inorganic materials 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229910052586 apatite Inorganic materials 0.000 claims 1
- 238000007486 appendectomy Methods 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 239000003462 bioceramic Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000032770 biofilm formation Effects 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 claims 1
- 229910001634 calcium fluoride Inorganic materials 0.000 claims 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002192 cholecystectomy Methods 0.000 claims 1
- 238000012321 colectomy Methods 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229910052878 cordierite Inorganic materials 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- GWWPLLOVYSCJIO-UHFFFAOYSA-N dialuminum;calcium;disilicate Chemical compound [Al+3].[Al+3].[Ca+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] GWWPLLOVYSCJIO-UHFFFAOYSA-N 0.000 claims 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 1
- 229940038472 dicalcium phosphate Drugs 0.000 claims 1
- JSKIRARMQDRGJZ-UHFFFAOYSA-N dimagnesium dioxido-bis[(1-oxido-3-oxo-2,4,6,8,9-pentaoxa-1,3-disila-5,7-dialuminabicyclo[3.3.1]nonan-7-yl)oxy]silane Chemical compound [Mg++].[Mg++].[O-][Si]([O-])(O[Al]1O[Al]2O[Si](=O)O[Si]([O-])(O1)O2)O[Al]1O[Al]2O[Si](=O)O[Si]([O-])(O1)O2 JSKIRARMQDRGJZ-UHFFFAOYSA-N 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 229910052587 fluorapatite Inorganic materials 0.000 claims 1
- 229940077441 fluorapatite Drugs 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000002241 glass-ceramic Substances 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002054 inoculum Substances 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000037000 normothermia Effects 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 238000006213 oxygenation reaction Methods 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 229910052628 phlogopite Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000011471 prostatectomy Methods 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000000153 supplemental effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- -1 vitlockite Chemical compound 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/849—Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Claims (17)
1. Biorazgradivi impregnirani supstrat ili čija je površina potpuno ili djelomično obložena matričnim sastavom koji sadrži (a) biorazgradivi poliestar, (b) prvu lipidnu komponentu koja sadrži najmanje jedan sterol koji je nekovalentno povezan s biorazgradivim poliestrom, (c) drugu lipidnu komponentu koja sadrži najmanje jedan fosfolipid koji ima dijelove masnih kiselina od najmanje 12 ugljika; i (d) antibiotsko sredstvo odabrano između doksiciklina i doksiciklin hiklata, za uporabu u liječenju ili profilaksi infekcije na mjestu incizije povezane s kirurškom operacijom kod subjekta kojem je to potrebno, pri čemu je supstrat mineralni supstrat oblikovan u obliku čestica.
2. Biorazgradivi supstrat za upotrebu sukladno patentnom zahtjevu 1, naznačen time, da infekcija uključuje površinsku incizijsku infekciju, infekciju dubokih incizija i infekciju organa/prostora.
3. Biorazgradivi supstrat za upotrebu sukladno patentnom zahtjevu 1, koristan za barem jedno smanjenja ukupne stope infekcije nakon operacije, iskorjenjivanja infekcija mekog tkiva koje mogu postojati prije operacije, inhibicije stvaranja biofilma na mjestu incizije i iskorjenjivanje postojećeg biofilma na mjestu incizije.
4. Biorazgradivi supstrat za upotrebu sukladno patentnim zahtjevima 1 do 3, gdje infekcija uključuje bolnički stečene rezistentne bakterije.
5. Biorazgradivi supstrat za upotrebu sukladno patentnim zahtjevima 1-4, naznačen time što je kirurška operacija odabrana između ortopedskih kirurških operacija, kirurških operacija na kralježnici, kirurških operacija na organu probavnog sustava, kardioloških zahvata, popravke kile, vaskularni zahvati, carskog reza, prostatektomije, opstetričke i ginekoloških kirurških operacija, kirurgije karcinoma glave i vrata, operacija transplantacije, neurokirurgije i plastičnih operacija.
6. Biorazgradivi mineralni supstrat za upotrebu sukladno patentnom zahtjevu 5, naznačen time da su kirurške operacije na organu probavnog sustava odabrane između jednjaka, želuca, tankog crijeva, debelog crijeva, rektuma, kolona, slijepog crijeva, jetre, gušterača, žučni mjehur, čira na želucu, zahvati protiv karcinoma želuca, otvorenog želučanog baypasa, apendektomije, kolektomije, holecistektomije, vagotomije, zahvati na otvorenom bilijarnom traktu, zahvati na tankom crijevu i kolorektalni zahvati.
7. Biorazgradivi supstrat za upotrebu sukladno patentnom zahtjevu 5, naznačen time da je kirurška operacija kardiološki kirurški zahvat, i pri čemu liječenje obuhvaća korak nanošenja obloženog supstrata na površinu sternalnih polovica i okolnog mekog tkiva.
8. Biorazgradivi supstrat za upotrebu sukladno bilo kojem od patentnih zahtjeva 1-7, za upotrebu u liječenju ili profilaksi infekcije mjesta incizije povezano s kirurškom operacijom kod subjekta kojem je to potrebno kao dodatak standardnim procedurama njege radi smanjenja bakterijskog inokuluma, odabranih iz skupine koju čine odgovarajuća priprema kirurškog mjesta, sustavni preventivni antibiotici, terapija zasnovana na stanicama i poboljšanje domaćina perioperativnom dodatnom oksigenacijom, održavanjem normotermije i kontrolom glikemije.
9. Biorazgradivi supstrat za upotrebu sukladno patentnim zahtjevima 1-8,
naznačen time da je biorazgradivi supstrat odabranih iz skupine koju čine hidroksiapatit, fluorapatit, oksiapatit, volastonit, apatit/volastonit staklo keramika, anortit, kalcijev fluorid, kalcijev sulfat, kalcijev karbonat, tetrakalcijev fosfat, α-trikalcijev fosfat (α-TCP), β-trikalcijev fosfat (β-TCP), amorfni kalcijev fosfat, dikalcijev fosfat, agrelit, devitrit, kanazit, flogopit, monetit, brušit, oktokalcijev fosfat, vitlokit, kordierit, berlinit, kombeit, kristali fosforne kiseline, dinatrijev hidrogen fosfat i druga biokeramika na bazi fosfatne soli.
10. Biorazgradivi mineralni supstrat za upotrebu sukladno patentnom zahtjevu 9, naznačen time, da je supstrat trikalcijev fosfat odabran između α-trikalcijevog fosfata (α-TCP) i β-trikalcijevog fosfata (β-TCP).
11. Biorazgradivi supstrat za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 9,
naznačen time da sastav matriksa sadrži fosfolipid odabran od fosfatidilholina ili kombinacije fosfatidilkolina koji imaju ostatke masnih kiselina koje imaju najmanje 12 ugljika;
poželjno gdje je navedeni fosfolipid fosfatidilkolin ili kombinacija fosfatidilkolina koji imaju ostatke masnih kiselina sa 14 - 18 ugljika.
12. Biorazgradivi supstrat za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 11,
naznačen time što je biorazgradivi poliester odabran iz skupine koju čine PLA (polimliječna kiselina), PGA (poliglikolna kiselina) i PLGA (poli (mliječna ko-glikolna kiselina).
13. Biorazgradivi supstrat za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 12,
naznačen time da matrični sastav nadalje sadrži farmaceutski aktivno sredstvo odabrano iz skupine sastavljene od antiseptičkog sredstva, antiupalnog sredstva, i antifungalnog sredstva; ili
gdje matrični sastav sadrži mnoštvo antibiotskih sredstava; ili
gdje matrični sastav nadalje sadrži najmanje jedno antiupalno sredstvo.
14. Biorazgradivi supstrat za upotrebu sukladno bilo kojem od patentnih zahtjeva 1-13,
naznačen time da je sterol u matričnom sastavu kolesterol;
poželjno gdje je težinski odnos ukupnih lipida prema navedenom biorazgradivom poliestru između 1:1 i 9:1 uključujući.
15. Biorazgradivi supstrat za upotrebu sukladno bilo kojem od patentnih zahtjeva, naznačen time da obloženi biorazgradivi supstrat sadrži između 60-90% (m/m) biorazgradivog supstrata i 10-40% (m/m) matričnog sastava, poželjno, gdje obloženi biorazgradivi supstrat sadrži između 70-90% (m/m) biorazgradivog supstrata i 10-30% (m/m) matričnog sastava.
16. Biorazgradivi supstrat za upotrebu sukladno bilo kojem od patentnih zahtjeva 1-15,
naznačen time, da je navedeni matrični sastav u osnovi bez vode;
poželjno pri čemu kada se obloženi biorazgradivi supstrat održava u vodenom okruženju, matrični sastav osigurava produženo oslobađanje navedenog antibiotskog sredstva, pri čemu se najmanje 30% navedenog antibiotskog sredstva oslobađa iz sastava kinetikom nultog reda.
17. Biorazgradivi supstrat za upotrebu sukladno patentnom zahtjevu 1, naznačen time, da matrični sastav sadrži: (a) 15-25% (m/m) poli (mliječne-ko-glikolne kiseline) (PLGA) (b) 5-15% (m/m) kolesterola; (c) 50-70% (m/m) smjese 1,2-dipalmitoil-sn-glicero-3-fosfoholina (DPPC) i l,2-distearoil-sn-glicero-3-fosfoholina (DSPC), pri čemu je odnos DPPC prema DSPC između 5:1 i 2:1 i (d) 7-12% (m/m) doksiciklina ili doksiciklin hiklata, pri čemu supstrat čini između 80-90% (m/m) i matrični sastav čini 10-20% (m/m) ukupne težine obloženog supstrata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462058809P | 2014-10-02 | 2014-10-02 | |
| EP15846726.6A EP3200748B1 (en) | 2014-10-02 | 2015-09-27 | Compositions and methods for the treatment and prophylaxis of surgical site infections |
| PCT/IB2015/057409 WO2016051321A1 (en) | 2014-10-02 | 2015-09-27 | Compositions and methods for the treatment and prophylaxis of surgical site infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211880T1 true HRP20211880T1 (hr) | 2022-03-04 |
Family
ID=55629498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211880TT HRP20211880T1 (hr) | 2014-10-02 | 2015-09-27 | Sastavi i metode za liječenje i profilaksu infekcija kirurškog mjesta |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20170246112A1 (hr) |
| EP (2) | EP3200748B1 (hr) |
| JP (2) | JP6899767B2 (hr) |
| KR (2) | KR20230175331A (hr) |
| CN (2) | CN106999356A (hr) |
| AU (1) | AU2015326428B2 (hr) |
| BR (1) | BR112017006406B1 (hr) |
| CA (1) | CA2963370C (hr) |
| CY (1) | CY1124795T1 (hr) |
| DK (1) | DK3200748T3 (hr) |
| EA (1) | EA201790383A1 (hr) |
| ES (1) | ES2900816T3 (hr) |
| HR (1) | HRP20211880T1 (hr) |
| HU (1) | HUE056523T2 (hr) |
| IL (1) | IL251351B (hr) |
| LT (1) | LT3200748T (hr) |
| MX (1) | MX2017004318A (hr) |
| NZ (1) | NZ729619A (hr) |
| PH (1) | PH12017500569A1 (hr) |
| PL (1) | PL3200748T3 (hr) |
| PT (1) | PT3200748T (hr) |
| RS (1) | RS62696B1 (hr) |
| SG (2) | SG10202012452UA (hr) |
| SI (1) | SI3200748T1 (hr) |
| WO (1) | WO2016051321A1 (hr) |
| ZA (1) | ZA201702884B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
| US20170246112A1 (en) * | 2014-10-02 | 2017-08-31 | Polypid Ltd. | Compositions and methods for the treatment and prophylaxis of surgical site infections |
| US20190091369A1 (en) * | 2016-04-11 | 2019-03-28 | Aroa Biosurgery Limited | Collagen-based device having antifungal properties |
| CN107929796A (zh) * | 2017-12-11 | 2018-04-20 | 河南亚都实业有限公司 | 生物止血膜 |
| CN108264373A (zh) * | 2018-02-06 | 2018-07-10 | 付主枝 | 医用增强型多孔生物陶瓷材料的制备方法 |
| CN113134116B (zh) * | 2020-01-20 | 2022-09-06 | 山东威高宏瑞医学科技有限公司 | 内镜微创手术用的填充组合物及填充制剂 |
| CN113456897A (zh) * | 2020-03-31 | 2021-10-01 | 威斯顿股份有限公司 | 生物材料及其用于促进组织再生的用途 |
| KR20240003296A (ko) | 2022-06-30 | 2024-01-08 | 주식회사 티온랩테라퓨틱스 | 당뇨발 및 수술부위 감염의 치료를 위한 지속형 항생제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040087520A1 (en) * | 2002-10-25 | 2004-05-06 | Chowdhury Dipak K. | Compositions and methods for delivery of therapeutic agents |
| US8277831B2 (en) * | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
| PL2299953T3 (pl) * | 2008-07-14 | 2017-10-31 | Polypid Ltd | Kompozycja nośnika leku o przedłużonym uwalnianiu |
| US9248159B2 (en) | 2008-10-14 | 2016-02-02 | Robert Stanley Berman | MRSA bactericidal topical gel |
| US9839628B2 (en) | 2009-06-01 | 2017-12-12 | Tyrx, Inc. | Compositions and methods for preventing sternal wound infections |
| IN2012DN00570A (hr) * | 2009-07-14 | 2015-06-12 | Polypid Ltd | |
| US8449916B1 (en) | 2009-11-06 | 2013-05-28 | Iowa State University Research Foundation, Inc. | Antimicrobial compositions and methods |
| EP2525778B1 (en) * | 2010-01-19 | 2018-08-01 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
| MX366048B (es) | 2012-08-02 | 2019-06-26 | Polypid Ltd | Composiciones y métodos para el tratamiento de vacíos óseos y fracturas expuestas. |
| US20170246112A1 (en) * | 2014-10-02 | 2017-08-31 | Polypid Ltd. | Compositions and methods for the treatment and prophylaxis of surgical site infections |
-
2015
- 2015-09-27 US US15/513,164 patent/US20170246112A1/en not_active Abandoned
- 2015-09-27 KR KR1020237043370A patent/KR20230175331A/ko active Application Filing
- 2015-09-27 KR KR1020177008467A patent/KR20170063638A/ko not_active IP Right Cessation
- 2015-09-27 HU HUE15846726A patent/HUE056523T2/hu unknown
- 2015-09-27 CN CN201580062206.XA patent/CN106999356A/zh active Pending
- 2015-09-27 SG SG10202012452UA patent/SG10202012452UA/en unknown
- 2015-09-27 ES ES15846726T patent/ES2900816T3/es active Active
- 2015-09-27 CA CA2963370A patent/CA2963370C/en active Active
- 2015-09-27 WO PCT/IB2015/057409 patent/WO2016051321A1/en active Application Filing
- 2015-09-27 JP JP2017516067A patent/JP6899767B2/ja active Active
- 2015-09-27 SI SI201531760T patent/SI3200748T1/sl unknown
- 2015-09-27 LT LTEPPCT/IB2015/057409T patent/LT3200748T/lt unknown
- 2015-09-27 PT PT158467266T patent/PT3200748T/pt unknown
- 2015-09-27 BR BR112017006406-5A patent/BR112017006406B1/pt active IP Right Grant
- 2015-09-27 MX MX2017004318A patent/MX2017004318A/es unknown
- 2015-09-27 HR HRP20211880TT patent/HRP20211880T1/hr unknown
- 2015-09-27 DK DK15846726.6T patent/DK3200748T3/da active
- 2015-09-27 EP EP15846726.6A patent/EP3200748B1/en active Active
- 2015-09-27 SG SG11201702469TA patent/SG11201702469TA/en unknown
- 2015-09-27 RS RS20211524A patent/RS62696B1/sr unknown
- 2015-09-27 EP EP21204657.7A patent/EP4094783A1/en active Pending
- 2015-09-27 NZ NZ729619A patent/NZ729619A/en unknown
- 2015-09-27 CN CN202310289934.0A patent/CN116473946A/zh active Pending
- 2015-09-27 PL PL15846726T patent/PL3200748T3/pl unknown
- 2015-09-27 AU AU2015326428A patent/AU2015326428B2/en active Active
- 2015-09-27 EA EA201790383A patent/EA201790383A1/ru unknown
-
2017
- 2017-03-23 IL IL251351A patent/IL251351B/en unknown
- 2017-03-27 PH PH12017500569A patent/PH12017500569A1/en unknown
- 2017-04-25 ZA ZA2017/02884A patent/ZA201702884B/en unknown
-
2020
- 2020-02-13 US US16/790,009 patent/US11471414B2/en active Active
-
2021
- 2021-01-08 JP JP2021001987A patent/JP7046237B2/ja active Active
- 2021-12-02 CY CY20211101054T patent/CY1124795T1/el unknown
-
2022
- 2022-08-11 US US17/819,008 patent/US11975101B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211880T1 (hr) | Sastavi i metode za liječenje i profilaksu infekcija kirurškog mjesta | |
| Uskokovic | Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis | |
| JP2017534585A5 (hr) | ||
| CA2518104C (en) | Artificial bone mineral substitute for in vivo hardening | |
| JP2021063123A5 (hr) | ||
| Van Vugt et al. | Biomaterials in treatment of orthopedic infections | |
| Morley et al. | Calcium sulphate as a drug delivery system in a deep diabetic foot infection | |
| BRPI1014607B1 (pt) | Vidro bioativo para o uso em condições relativas a infecções ósseas | |
| EP2353619A1 (en) | Preparation of Bone Cement Compositions | |
| EP3378503A2 (en) | Calcium based clinical material with antimicrobial properties and method of forming for prevention or treatment of infection | |
| Howlin et al. | Prevention of Propionibacterium acnes biofilm formation in prosthetic infections in vitro | |
| JP6182213B2 (ja) | 骨空洞および開放骨折の治療のための組成物および方法 | |
| Su et al. | A new type of biphasic calcium phosphate cement as a gentamicin carrier for osteomyelitis | |
| Tsai et al. | Effects of the addition of vancomycin on the physical and handling properties of calcium sulfate bone cement | |
| Zambanini et al. | Bioactive glasses for treatment of bone infections | |
| CA2961998C (en) | Methods for the treatment of peri-implantitis | |
| Manchon et al. | Antibiotic release from calcium phosphate materials in oral and maxillofacial surgery. molecular, cellular and pharmaceutical aspects | |
| JP2020510006A (ja) | バイオフィルム形成を阻害するためのリポソーム | |
| Lukina et al. | Composite brushite-monetite-newberyite cements loaded with vancomycin and their efficiency against infections of: In vitro and in vivo research | |
| Chou et al. | Calcium phosphate derived from foraminifera structures as drug delivery systems and for bone tissue engineering | |
| EA041251B1 (ru) | Применение фармацевтической композиции для лечения или профилактики инфекций области разреза при хирургическом вмешательстве |